Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Breast Cancer Symposium
Comparative Effectiveness Research Should Reap Benefits for Oncology Care
By
Audrey Andrews
Breast Cancer
,
Breast Cancer Symposium
,
Solid Tumors
October 2013, Vol 4, No 8
San Francisco, CA—Comparative effectiveness research (CER) is an important construct for identifying and summarizing the evidence on the effectiveness, safety, and overall value of alternative strategies in oncology care, said Gary H. Lyman, MD, MPH, Professor of Medicine, Duke University and the Duke Cancer Research Institute, Durham, NC, during the 2013 Breast Cancer Symposium.
Read Article
Current Patterns and Costs of Treating Patients with Metastatic Breast Cancer
By
Audrey Andrews
Breast Cancer
,
Breast Cancer Symposium
,
Solid Tumors
October 2013, Vol 4, No 8
San Francisco, CA—In a population of patients with metastatic breast cancer and Medicare Part D claims, the mean lifetime cost of treatment was approximately $102,000, according to a study presented at the 2013 Breast Cancer Symposium by Hope S. Rugo, MD, Director, Breast Oncology Clinical Trials Program, University of California, San Francisco.
Read Article
Role of Radiation and Imaging in DCIS Explained
By
Phoebe Starr
Breast Cancer
,
Breast Cancer Symposium
,
Solid Tumors
October 2013, Vol 4, No 8
San Francisco, CA—Management of ductal carcinoma in situ (DCIS) was the focus of 2 studies highlighted at a press conference before the 2013 Breast Cancer Symposium.
Read Article
For Oncologists, Some Food for Thought in the New Era of Healthcare Reform
By
Audrey Andrews
Breast Cancer
,
Breast Cancer Symposium
,
Solid Tumors
October 2013, Vol 4, No 8
San Francisco, CA—At the 2013 Breast Cancer Symposium, Lawrence N. Shulman, MD, Senior Vice President for Medical Affairs, Dana-Farber Cancer Institute, Boston, told oncologists that in the current era of healthcare reform, they will need to think beyond treatment outcomes, toxicities, and personal preferences.
Read Article
No Increase in Leukemia or MDS with Adjuvant Chemotherapy for Breast Cancer
By
Audrey Andrews
Breast Cancer Symposium
November 2012, Vol 3, No 8
San Francisco, CA—According to a study from the US Oncology Network, patients with breast cancer who are treated with adjuvant chemotherapy have no increased risk for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), at least within the first 3 years of treatment.
Read Article
Costly Acute Care Episodes Are Common for Patients with Early Breast Cancer
Breast Cancer Symposium
November 2012, Vol 3, No 8
San Francisco, CA—Acute care utilization, namely, emergency department visits and hospitalizations, are surprisingly common among patients with early breast cancer, according to a retrospective study using an administrative database in Ontario, Canada.
Read Article
Some Staging Studies Not Beneficial in Early Breast Cancer Work-Up
By
Caroline Helwick
Breast Cancer Symposium
November 2012, Vol 3, No 8
San Francisco, CA—Three frequently used radiologic tests rarely detect metastases in patients with a new diagnosis of breast cancer and should not be routinely performed, according to a comprehensive literature review presented at the 2012 Breast Cancer Symposium.
Read Article
Oncotype DX Score Predicts Residual Disease after Chemotherapy
By
Audrey Andrews
Breast Cancer Symposium
November 2012, Vol 3, No 8
San Francisco, CA—The Oncotype DX Recurrence Score (the 21-gene) test can help identify patients with estrogen receptor (ER)-positive breast cancer with any number of positive lymph nodes who will have residual disease after adjuvant chemotherapy, and who may benefit from additional treatment, reported Eleftherios P. Mamounas, MD, Medical Director, Aultman Hospital Cancer Center, Canton, OH, at the 2012 Breast Cancer Symposium.
Read Article
Fewer Therapy Delays with Palonosetron than with Similar Antiemetics
Breast Cancer Symposium
October 2012, Vol 3, No 7
San Francisco, CA—An analysis of a large claims database showed that patients with breast cancer had fewer delays in chemotherapy and maintained better adherence to their regimens when treated with the 5-hydroxytryptamine 3 (5-HT3) receptor antagonist palonosetron (Aloxi) than with other agents in this antiemetic class.
Read Article
More Evidence Supports the Anticancer Effect of Metformin
By
Charles Bankhead
Breast Cancer Symposium
October 2012, Vol 3, No 7
San Francisco, CA—Women with diabetes taking metformin had a significantly lower risk of breast cancer, an association that appeared to grow stronger with increasing duration of follow-up, results of a recent meta-analysis showed.
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma